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Persistent negative symptoms are associated with worse outcome in
both first-episode and chronic subjects with schizophrenia. The
identification of these symptoms in recent-onset subjects is still
controversial as retrospective data are often unavailable. The pro-
spective assessment of persistence of negative symptoms might
represent a valid alternative but the length of the persistence is still
to be established. The present study investigated the prevalence of
negative symptoms of moderate severity, unconfounded by depres-
sion and extrapyramidal symptoms at baseline in a large cohort of
patients in the early stage of a schizophrenia-spectrum disorder,
recruited to the OPTiMiSE trial. Persistent unconfounded negative
symptoms were assessed at 4, 10 and 22 weeks of treatment. Symp-
tomatic remission, attrition rate and psychosocial functioning was
evaluated in subjects with short-term (4 weeks) persistent negative
symptoms (PNS) and in those with negative symptoms that did not
persist at follow-up and/or were confounded at baseline (N-PNS).
Negative symptoms of moderate severity were observed in 59% of
subjects at baseline and were associated to worse global functioning.
PNS were observed in 7.9% of the cohort, unconfounded at both
baseline and end of 4-week treatment. PNS subjects showed lower
remission andhigher attrition rates at the end of all treatment phases.
Fifty-six percent of subjects completing phase 3 (clozapine treat-
ment) had PNS, and 60% of them were non-remitters at the end of
this phase. The presence of short-termPNS during the first phases of
psychosis was associatedwith poor clinical outcome and resistance to
antipsychotic treatment, including clozapine.
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Negative symptoms are a core feature of schizophrenia spectrum
disorders associated with poor outcomes such as low remission
rates and impairments in daily functioning and quality of life in
early psychosis. The assessment of negative symptoms in early
psychotic disorders is predominantly conducted by use of first-
generation scales such as the PANSS and the SANS, along with the
SIPS and CAARMS for the psychosis clinical high-risk (CHR) state.
Following the progressed conceptualization of negative symptoms,
it has, however, been recognized that these scales suffer important
methodological limitations. This warrants a use of second-
generation scales such as the Brief Negative Symptom Scale
(BNSS) and the Clinical Assessment Interview for Negative Symp-
toms (CAINS) in early intervention settings in order to achieve a
more accurate assessment of the negative symptom complex.
Advancing the assessment of negative symptoms in early psychosis
may also guide more targeted intervention approaches aimed at
improving functional outcome. Albeit recognizing that negative
symptoms constitute an important barrier to a good functional
outcome in psychotic disorders, few studies have directly aimed at
alleviating negative symptoms in early psychosis. Meta-analytical
evidence does, however, exist on the efficacy of the combined
treatment modalities incorporated in Early Intervention Services
(e.g. intensive and assertive case management, family involvement
etc.) in reducing negative symptoms in first-episode psychosis.
Evidence on the effect of interventions for improving negative
symptoms in the CHR state is lacking. Developing targeted, and
possibly more individualized negative symptoms treatment
approaches, constitute an essential future research area.
Disclosure: No significant relationships.
Keywords: Assessment negative symptoms; Negative symptoms
early psychosis; Functional outcome early psychosis
S0128
The challenges in schizophrenia treatment in real-life:
The uncomfortable truth
E. Rancans
Department Of Psychiatry And Narcology, Riga Stradins University,
Riga, Latvia
doi: 10.1192/j.eurpsy.2021.125
Certain percentage of the first-episode schizophrenia patients pre-
sents with negative symptoms, which persists over the year and
influence treatment outcomes (Galderisi et al. 2013). Treatment of
negative symptoms has been a significant continuous clinical chal-
lenge. Majority of recently published guidelines recommend anti-
psychotic monotherapy as the standard of care, recommending
antipsychotic combination therapy only after a failed trial with
clozapine (George A. Keepers et al. 2020; Faden et al. 2020). How-
ever, real-life forces clinicians to look for possible combinations of
medications early on, especially to tackle negative symptoms. The
systematic review of global prescribing practices covering four
decades found the pooled median rate of antipsychotic combination
therapy approximately 20% (Gallego et al. 2012). One of the largest
retrospective studies every conducted (n = 62,250) assessed rehospi-
talisation rates and the long-termuse of antipsychotic polypharmacy
in schizophrenia. Antipsychotic combination treatment was associ-
ated with an approximate 10% lower relative risk of psychiatric
rehospitalisation compared with antipsychotic monotherapy
(Tiihonen et al. 2019). Real-world effectiveness study of antipsy-
chotic monotherapy vs. polypharmacy in schizophrenia from East-
ern Europe is also supporting this approach (Katona, Czobor, and
Bitter 2014). At the same time antipsychotic combination therapy
can increase the total antipsychotic dose burden, frequency of
adverse effects, potential drug-drug interactions and incur additional
costs. In our recent naturalistic study in schizophrenia outpatients
(n=120) with insufficient effectiveness of previous antipsychotics
S36 Symposium
therapy on negative symptoms, we were able successfully switch
therapy form several different antipsychotic combinations to mono-
therapy and gain clinical benefits (Rancans et al, 2020).
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Background: Individuals with mental illness may be particularly
vulnerable to the negative impact that the coronavirus disease 2019
(COVID-19) pandemic seems to have onmental health. Most prior
studies on this topic are however limited by non-random sampling,
lack of information on non-respondents, and self-reported diagno-
ses. Here, we aimed at overcoming these limitations by means of
random sampling in a population of clinically diagnosed patients,
acquisition of clinical and socio-demographic data on non-
respondents, and weighting of results informed by attrition.
Methods: We conducted a cross-sectional questionnaire-based
online survey inviting six-thousand randomly drawn patients from
the psychiatric services of the Central Denmark Region. They
survey data were merged with sociodemographic- and clinical data
from medical records on all invitees, which enabled analysis of
attrition and weighting of results. The questionnaire included the
18-item Brief Symptom Inventory (BSI-18), the 5-item World
HealthOrganizationWell-Being Index (WHO-5), and 14 questions
evaluating the perceived severity of symptoms during the four-
week nationwide lockdown of Denmark in March/April 2020 –
using the pre-pandemic period as reference. Reasons for worsening
or improvement in mental health during lockdown were also
reported.
Results: The preliminary results are as follows: The response rate
was ≈20%. Approximately half the respondents reported that their
mental health had deteriorated during lockdown, while the other
half reported either no change (≈33%) or improvement (≈16%).
The most commonly reported reasons for deterioration in mental
health were disruption of routines and loneliness.
Conclusion: The final results will be shown at the conference.
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The future of psychiatry as a discipline (and as the main source of
knowledge in the construction and functioning o mental health
services) can best be grasped on the basis of an examination of the
development of psychiatry over the past century in the light of
current options for its functioning. Such an examination demon-
strates that psychiatrists will have to expand their field of work to
include the management of comorbidity of mental and physical
disorders and public health approaches to the primary prevention
of mental and other brain disorders. Their engagement in research
will have to become restricted to psychopathology and participa-
tion in the formulation of hypotheses which will be tested in
laboratory and field work;; and their involvement in teaching about
mental health and illness will have to undergo a fundamental
change in terms of content, methods and evaluation of effects of
education which they will organize. The presentation will focus on
the future tasks of psychiatrists in these areas
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For a Mid-career Professor in Germany, there are defined clinical
and teaching responsibilities. One can focus either on one’s
research or on clinical work and teaching.When tasks are becoming
more demanding or significant overarching decisions need to be
taken, there is always a chairperson to be asked or to help delegate
tasks. As chairperson, one is mostly independent from other per-
sons except for the dean of the medical faculty. One is however, at
least in Germany, the chairpersons fully responsible for keeping up
teaching, patient care, research as well as running the department.
The Chairperson is measured by the achievements of these four
tasks. It need special attention to keep up a balanced time schedule
to cover clinical care, research, teaching and departmental man-
agement. A good chairs means working together with your staff on
long-term goals, developing the department fruitfully and trying to
fulfil these goals.
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